Showing 2701-2710 of 4166 results for "".
- Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Modelhttps://modernod.com/news/aldeyra-therapeutics-announces-publication-of-phase-2-clinical-trial-of-reproxalap-in-allergen-chamber-model/2480608/Aldeyra Therapeutics announced that results from the randomized, double-masked, vehicle-controlled, crossover phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.1 Reproxalap, an
- Aldeyra Therapeutics Announces Achievement of Primary Endpoint in Phase 2 Clinical Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-achievement-of-primary-endpoint-in-phase-2-clinical-trial-in-dry-eye-disease/2480392/Aldeyra Therapeutics announced achievement of the primary endpoint of ocular redness in a randomized, double-masked, vehicle-controlled phase 2 clinical trial in patients with dry eye disease. The clinical trial enrolled 158 patients: 80 patients were randomized to receive 0.25% re
- Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trialshttps://modernod.com/news/dopavision-closes-e12-million-series-a-round-to-advance-digital-childhood-myopia-therapeutic-through-clinical-trials/2479372/Dopavision announced the closing of a €12 million Series A financing round. The proceeds will be used to fund the clinical development of MyopiaX, the company’s lead product in childhood myopia, with the goal to demonstrate its safety and efficacy in clinical studies and advance this innova
- Glaukos Completes Patient Enrollment in US NDA Phase 3 Clinical Trials for iDose TRhttps://modernod.com/news/glaukos-completes-patient-enrollment-in-us-nda-phase-3-clinical-trials-for-idose-tr/2479280/Glaukos announced the completion of patient enrollment and randomization in its FDA new drug application (NDA) phase 3 clinical trials for the iDose TR sustained-release travoprost implant. The iDose TR phase 3 clinical program consists of two prospective, randomized, double-
- Salvat Completes Phase 3 Clinical Trials of its New Ophthalmic Corticosteroid Nanoemulsionhttps://modernod.com/news/salvat-completes-phase-3-clinical-trials-of-its-new-ophthalmic-corticosteroid-nanoemulsion/2479254/Salvat has completed the phase 3 clinical trials in the US for its drug candidate for the treatment of ocular inflammation and pain after cataract surgery. The clinical trials started in 2020 and include 400 adult patients who had recently undergone cataract surgery in 50 US hospitals. Res
- Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercepthttps://modernod.com/news/novartis-sandoz-unit-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2479166/Sandoz, a division of Novartis, announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical phase 3 confirmatory efficacy and safety study, shortly.1 Aflibercept (
- Hovione Completes Phase 2 Clinical Trial of First Minocycline Ophthalmic for Dry Eye Disease Associated With Inflamed MGDhttps://modernod.com/news/hovione-completes-phase-2-clinical-trial-of-first-minocycline-ophthalmic-showing-promise-in-dry-eye-disease-associated-with-inflamed-mgd/2478986/Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its phase 2 clinical trial in 270 patients with dry eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patientshttps://modernod.com/news/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients/2478948/Alteogen announced that it has completed phase 1 clinical trial of Eylea Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened compet
- Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophyhttps://modernod.com/news/trefoil-therapeutics-begins-second-phase-2-storm-clinical-trial-with-regenerative-treatment-for-fuchs-endothelial-corneal-dystrophy/2478856/Trefoil Therapeutics announced it has begun a phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD). The “STORM” study, the second clinical trial o